protein kinase cAMP-dependent type II regulatory subunit betaGenealiases: PRKAR2 · RII-BETA
Q-omics provides the consensus-scored PRKAR2B profile across patient tissues and cancer cell-line models. PRKAR2B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, PRKAR2B is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, PRKAR2B protein abundance shows 35,443 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SKCM, KIRC, and GBM as cancer lineages where PRKAR2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRKAR2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRKAR2B survival associations across molecular data types. PRKAR2B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRKAR2B RNA expression–survival associations across cancer types. High PRKAR2B expression shows unfavorable associations in UVM, ACC and LAML, but favorable associations in SKCM, HNSC and PAAD. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for PRKAR2B RNA expression.
This table summarizes PRKAR2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 12. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PRKAR2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PRKAR2B shows lower tumor expression in KIRC, BLCA, KICH, COAD, THCA and LUSC. The KIRC box plot shows higher PRKAR2B RNA expression in normal versus tumor tissue (log2 FC = −2.005, t-test p < 0.001).
This table shows molecular features associated with PRKAR2B in patient tissues and cancer cell lines. In patient samples, PRKAR2B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, PRKAR2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Leukemia.
